Search results for "Liposomal Doxorubicin"

showing 7 items of 7 documents

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC

2016

// Francesco Perrone 1,* , Gustavo Baldassarre 2,* , Stefano Indraccolo 3,* , Simona Signoriello 4 , Gennaro Chiappetta 1 , Franca Esposito 5 , Gabriella Ferrandina 6 , Renato Franco 1,15 , Delia Mezzanzanica 7 , Maura Sonego 2 , Elisabetta Zulato 3 , Gian F. Zannoni 6 , Vincenzo Canzonieri 2 , Giovanni Scambia 6 , Roberto Sorio 2 , Antonella Savarese 8 , Enrico Breda 9 , Paolo Scollo 10 , Antonella Ferro 11 , Stefano Tamberi 12 , Antonio Febbraro 13 , Donato Natale 14 , Massimo Di Maio 1,16 , Daniela Califano 1 , Giosue  Scognamiglio 1 , Domenica Lorusso 7 , Silvana Canevari 7 , Simona Losito 1 , Ciro Gallo 4,** and Sandro Pignata 1,** 1 Istituto Nazionale per lo Studio e la Cura dei Tumor…

0301 basic medicinemedicine.medical_specialtyLiposomal Doxorubicinovarian cancer; phase 3 clinical trial; predictive factors; pACC; DNA-PKDNA-Activated Protein KinaseDisease-Free Survivalpredictive factorDNA-PK03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerPhase 3 clinical trialAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansDNA-PK; ovarian cancer; pACC; phase 3 clinical trial; predictive factorsGynecologyOvarian NeoplasmsAdvanced ovarian cancerphase 3 clinical trialbusiness.industrySignificant differenceDNA-PK; Ovarian cancer; PACC; Phase 3 clinical trial; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; DNA-Activated Protein Kinase; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Prognosismedicine.diseasePrognosisPredictive valuePACCCarboplatinhumanitiesFirst line treatmentovarian cancer030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemalebusinessOvarian cancerPredictive factorsResearch PaperpACC
researchProduct

A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma

2006

We carried out a phase II nonrandomized study to examine the level of activity of oxaliplatin, pegylated liposomal doxorubicin, and cyclophosphamide in a patient population with relapsed ovarian cancer pretreated with platinum derivatives and paclitaxel. Patients received oxaliplatin (85 mg/m2), pegylated liposomal doxorubicin (30 mg/m2), and cyclophosphamide (750 mg/m2). A total of 49 patients (39 assessable for toxicity and response) were enrolled in this trial. Neutropenia grade 3 was observed in six patients (15%) and anemia grade 3 in one patient (0.2%). Fatigue grade 1–2 occurred in 26 patients (66%), nausea/vomiting grade 1 in 23 patients (58%), and alopecia grade 1–2 in 19 patients …

AdultOncologyTRIAL COMPARING CISPLATINmedicine.medical_specialtysecond-line therapy PLATINUM-BASED CHEMOTHERAPYOrganoplatinum CompoundsCyclophosphamidemedicine.medical_treatmentPhases of clinical researchAdenocarcinomaNeutropeniaPACLITAXELchemotherapyGastroenterologySINGLE-AGENTPolyethylene GlycolsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineEVALUATETOPOTECANCOMBINATIONCyclophosphamideAgedOvarian NeoplasmsChemotherapybusiness.industrySALVAGE CHEMOTHERAPYoxaliplatinObstetrics and GynecologyCombination chemotherapyMiddle Agedmedicine.diseaseSurvival AnalysisCANCEROxaliplatinRegimenliposomal doxorubicinovarian cancerOncologyDoxorubicinFemaleNeoplasm Recurrence LocalbusinessOvarian cancerFOLLOW-UPmedicine.drug
researchProduct

Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer.

2022

Background. The use of anthracyclines in metastatic breast cancer (MBC) is limited by cumulative dose-dependent cardiotoxicity mostly in elderly women with comorbidities. The aim of this observational retrospective study was to evaluate the efficacy of non-pegylated liposomal doxorubicin (Myocet®) and cyclophosphamide in elderly women as HER2 negative first-line MBC treatment. Methods. 84 elderly women >70 years of age (median age 78 years) with MBC HER2 negative were enrolled. Performance Status in 58 patients was ECOG-0 and in 26 patients was ECOG-1. Results. The drug was well tolerated, with overall response rates were >40%, median overall survival was 16.2 months (95%CI:14.6- 18.8…

Ca 15-3 Cyclophosphamide Elderly woman Metastatic breast cancer Non-pegylated liposomal doxorubicin Quality of lifeTreatment OutcomeDoxorubicinAntineoplastic Combined Chemotherapy ProtocolsHumansBreast NeoplasmsFemaleCyclophosphamideCardiotoxicityAgedPolyethylene GlycolsRetrospective StudiesLa Clinica terapeutica
researchProduct

Pegylated liposomal doxorubicin in the management of ovarian cancer

2014

Ovarian cancer is the leading cause of death among gynecological tumors. Carboplatin/paclitaxel represents the cornerstone of front-line treatment. Instead, there is no consensus for management of recurrent/progressive disease, in which pegylated liposomal doxorubicin (PLD) ± carboplatin is widely used. We performed a systematic review and metaanalysis to evaluate impact of PLD-based compared with no-PLD-based regimens in the ovarian cancer treatment. Data were extracted from randomized trials comparing PLD-based treatment to any other regimens in the January 2000-January 2013 time-frame. Study end-points were overall survival (OS), progression free survival (PFS), response rate (RR), CA125…

MetaanalysiOncologyCancer Researchmedicine.medical_specialtyendocrine system diseasesPharmacologyarian cancerDisease-Free SurvivalPolyethylene Glycolslaw.inventionchemistry.chemical_compoundRandomized controlled triallawOvPegylated liposomal doxorubicinInternal medicinemedicineHumansProgression-free survivalSystemic chemotherapyProportional Hazards ModelsRandomized Controlled Trials as TopicOvarian NeoplasmsPharmacologyAntibiotics Antineoplasticbusiness.industryProportional hazards modelHazard ratiomedicine.diseaseCarboplatinTreatment OutcomeOncologychemistryTolerabilityDoxorubicinClinical StudyMolecular MedicineFemaleRandomized clinical trialbusinessOvarian cancerProgressive diseaseCancer Biology & Therapy
researchProduct

Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer. Preliminary activity results of the MITO-2 phase III trial

2008

<i>Background:</i> Based on the efficacy of pegylated liposomal doxorubicin (PLD) in relapsed ovarian cancer, we are conducting a phase III study comparing carboplatin plus either paclitaxel or PLD as first-line therapy in advanced ovarian cancer. Because of limited phase I and II data on PLD plus carboplatin in this setting, we conducted an interim activity analysis. <i>Patients and Methods:</i> Patients with stage 1c-IV epithelial ovarian cancer were randomized to carboplatin AUC 5 plus either paclitaxel 175 mg/m<sup>2</sup> or PLD 30 mg/m<sup>2</sup> every 3 weeks for 6 cycles. The interim activity analysis was planned according to a single…

Oncologyarea under curveCancer Researchendocrine system diseasesmedicine.medical_treatmentneoplasmspolyethylene glycolsantibioticsPegylated Liposomal Doxorubicinsurvival analysischemistry.chemical_compoundpaclitaxelmiddle agedantineoplastic agentsNeoplasms Glandular and EpithelialhumansanthracyclinesAntibiotics AntineoplasticadultGeneral Medicineovarian neoplasmsfemale genital diseases and pregnancy complicationsagedovarian cancerfemaleOncologyPaclitaxelcarboplatinlipids (amino acids peptides and proteins)Anthracyclinesmedicine.drugmedicine.medical_specialtyantineoplasticantineoplastic combined chemotherapy protocolsglandular and epithelialdoxorubicinpegylated liposomal doxorubicinInternal medicineanthracyclines; carboplatin; ovarian cancer; paclitaxel; pegylated liposomal doxorubicin; adult; aged; antibiotics antineoplastic; antineoplastic agents; antineoplastic combined chemotherapy protocols; area under curve; carboplatin; doxorubicin; female; humans; middle aged; neoplasm staging; neoplasms glandular and epithelial; ovarian neoplasms; paclitaxel; polyethylene glycols; survival analysis; treatment outcomemedicineDoxorubicinneoplasm stagingAdvanced ovarian cancerChemotherapybusiness.industryCancermedicine.diseaseCarboplatinEndocrinologychemistrytreatment outcomebusinessOvarian cancer
researchProduct

Pegylated liposomal doxorubicin (PLD) and weekly paclitaxel (P) as second line chemotherapy in metastatic bladder cancer.

2008

bladder cancer Pegylated liposomal doxorubicin (PLD)weekly paclitaxel
researchProduct

A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?

2012

Abstract Background Ovarian cancer (OC) is the sixth most common cancer in women. Currently, carboplatin/paclitaxel ± bevacizumab is the cornerstone of front-line treatment. Conversely, the therapeutic options for recurrent or progressive disease are not well defined. For platinum-sensitive patients the best therapeutic approach is still a re-challenge with a platinum-based regimen. Pegylated liposomal doxorubicin (PLD), is considered one of the most active therapeutic options for recurrent or progressive OC. In this retrospective mono-institutional analysis, we evaluated the impact of PLD on the outcome of OC patients. Patients and methods We performed the retrospective study on a cohort o…

medicine.medical_specialtyBevacizumabUrologySecond line treatmentchemistry.chemical_compoundOvarian cancerPegylated liposomal doxorubicinObstetrics and GynaecologymedicineStage (cooking)Systemic chemotherapyGynecologyPlatinum refractory patientsbusiness.industryResearchObstetrics and GynecologyCancerRetrospective cohort studymedicine.diseaseCarboplatinRegimenenzymes and coenzymes (carbohydrates)OncologychemistryPlatinum refractory patientlipids (amino acids peptides and proteins)Ovarian cancerbusinessProgressive diseasemedicine.drugJournal of ovarian research
researchProduct